YAP plays a crucial role in KRAS-mutation-driven tumorigenesis of pancreatic ductal adenocarcinoma [30], and we previously identified that YAP/TAZ expressions participate in the resistance of anti-EGFR therapy in KRAS-mutant NSCLC [26]. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.